411 results about "Cell Membrane Proteins" patented technology

The invention discloses a fermentation method of recombinant bacillus subtilis for expressing vibrio parahaemolyticus outer membrane protein, which comprises the following steps: inoculating a recombinant bacillus subtilis strain into a liquid culture medium for activation and amplification to obtain a seed solution; transferring the seed solution into a fermentation tank according to the inoculum size of 5%-10%, controlling the temperature to be 35-37 DEG C and the pH to be 6.8-7.2, introducing sterile air and stirring, and monitoring the thallus concentration OD600 value in real time; when the OD600 value reaches 35-38, 10% of an inducer is added for pre-induction; when the OD600 value reaches 40-45, the remaining 90% of the inducer is added for main induction, and the real-time dissolved oxygen value is collected; when the real-time dissolved oxygen value is continuously higher than a first preset threshold value, the flow acceleration rate of the inducer is increased, the fermentation temperature is increased at the same time or step by step, and the increase amplitude of the dissolved oxygen value is in positive correlation with the flow acceleration rate and the temperature increase amplitude; when the OD600 value is stabilized in a preset interval, it is judged that fermentation is completed, and the recombinant bacillus subtilis thalli are obtained. The yield and quality of the vibrio parahaemolyticus outer membrane protein can be effectively improved.

The invention discloses a hair follicle targeting nano-liposome anti-hair loss and hair growth compound preparation. The compound preparation is prepared from the following raw materials in parts by mass: 70 to 85 parts of bionic liposome carrier and 15 to 30 parts of active ingredients, the bionic liposome carrier is prepared from 50 to 60 parts of egg yolk lecithin, 15 to 20 parts of pH sensitive phospholipid DOPE, 10 to 15 parts of cholesterol and 5 to 10 parts of mesenchymal stem cell exosome membrane protein; the active ingredients comprise 5 to 10 parts of minoxidil, 3 to 5 parts of caffeine, 0.5 to 1 part of miR-218-5p, 1 to 2 parts of biotin and 2 to 3 parts of quercetin; the average particle size of the nano-liposome formed by the bionic liposome carrier is 120-180nm, and the polydispersity index (PDI) is less than or equal to 0.15. The invention relates to the technical field of biological medicines, in particular to a hair follicle-targeted nano-liposome anti-hair loss and hair growth compound preparation, which has the following advantages due to the adoption of the technical scheme: accurate targeted delivery is realized, and the treatment safety and accuracy are improved; intelligent response release is achieved, and the local microenvironment of hair follicles is optimized; the multi-target synergistic effect breaks through the limitation of single treatment.

The invention provides a recombinant chicken antibacterial peptide aiming at drug-resistant staphylococcus aureus, and belongs to the technical field of veterinarians. The recombinant chicken antibacterial peptide is expressed through genetic engineering recombinant escherichia coli. Three natural chicken antibacterial peptide active regions are fused, and two disulfide bonds are introduced to stabilize the structure of the recombinant chicken antibacterial peptide and enhance the affinity of the recombinant chicken antibacterial peptide to staphylococcus aureus outer membrane protein. The minimum inhibitory concentration of the recombinant chicken antibacterial peptide to the drug-resistant staphylococcus aureus is obviously lower than that of three natural chicken antibacterial peptides, and the formation of a biomembrane of a USA300 strain of the drug-resistant staphylococcus aureus can be thoroughly inhibited when the minimum inhibitory concentration is 8 mu g / mL. The recombinant chicken antibacterial peptide has a good antibacterial effect on different drug-resistant staphylococcus aureus separated from a chicken house, and can effectively solve the infection problem of the drug-resistant staphylococcus aureus in the chicken house.

The invention discloses an EV membrane protein single molecule detection method based on droplet microfluidics and application thereof. The method comprises the following steps: firstly, constructing an Ab-oligo compound which is formed by sequentially connecting an antibody, Linker, Linker connection DNA, RNA capable of being specifically cut by RNA enzyme and template DNA for starting signal amplification; then capturing the extracellular vesicles in the plasma by using the CD9 / CD63 / CD81 functionalized magnetic beads; the method comprises the following steps: adding an Ab-oligo compound and a sealing buffer solution into extracellular vesicles, incubating, removing the uncombined Ab-oligo compound, adding RNA enzyme for incubating and enzyme digestion, collecting template DNA for starting signal amplification, and performing microdroplet digital PCR analysis to realize single molecule analysis of EV membrane protein. According to the invention, the one-to-one correspondence relationship between the antibody and oligonucleotide is established through Linker for the first time, single protein information is converted into single nucleic acid chain information, and EV membrane protein single molecule detection is realized. The method is simple to operate, can qualitatively and quantitatively detect the single EV membrane protein, and is beneficial to further research on the relationship between the EV membrane protein and diseases.

The invention discloses a cell membrane protein replacement type oncolytic virus vector and application thereof. The cell membrane protein replacement type oncolytic virus vector is rhabdoviridae virus, and a nucleotide sequence for coding G protein in a genome of the rhabdoviridae virus is replaced by a nucleotide sequence for coding an antibody and a nucleotide sequence for coding a spike protein truncation of coronavirus. The invention also discloses a construction method of the cell membrane protein replacement type oncolytic virus vector for expressing the antibody, the non-replicated virus vector is used for expressing the antibody sequence for the first time, and meanwhile, the novel coronavirus cell membrane protein is embedded into the virus surface, so that the cell membrane protein replacement type oncolytic virus vector can be rapidly produced in a suspension cell in a large scale; through removal of virus cell membrane protein genes, the virus cell membrane protein genes cannot be continuously replicated in vivo, so that the safety of the virus cell membrane protein genes is ensured, the tumor immunosuppression condition is improved, and an organism can be stimulated to generate a neutralizing antibody for resisting new coronavirus while tumor cells are killed.

The invention belongs to the technical field of biological medicine, and particularly relates to an engineered cell microvesicle and a delivery system based on the engineered cell microvesicle, the system realizes efficient preparation of 1-5 [mu] m cell microvesicles, and the cell microvesicles have a large space volume and can be used for preparing the cell microvesicles. The carrier can be used for loading and delivery of target protein, polypeptide and recombinase which are specifically expressed in mother cells. The system transfects mother cells through lentivirus transfection or plasmid transfection to further produce cell microvesicles, and the microvesicles can load more goods and inherit membrane proteins of the mother cells, and can also effectively load intracellular proteins to realize effective delivery. By virtue of good structural stability, high immunogenicity and excellent biocompatibility, the cell microvesicle reduces systematic toxic and side effects of a traditional carrier, is expected to become an effective drug delivery system, and has great application potential in the field of gene therapy.

Disclosed are fusion proteins (and homodimers and heterodimers thereof). Fusion proteins can bind to a protein of interest and to an internalizing receptor (transferrin receptor) on a cell surface. Once bound, the protein of interest can be internalized and / or degraded inside a cell.

The invention discloses a sheep paratuberculosis specific detection kit and application, and relates to the field of biological detection.The kit comprises an elisa plate coated with a recombinant Mycobacterium paratuberculosis membrane protein antigen, the nucleotide sequence of the recombinant Mycobacterium paratuberculosis membrane protein antigen is shown as SEQ ID NO: 1, and the amino acid sequence of the recombinant Mycobacterium paratuberculosis membrane protein antigen is shown as SEQ ID NO: 2; a confining liquid; a serum diluent; carrying out enzyme labeling on a second antibody; a TMB color developing solution and a stop solution; according to the sheep paratuberculosis specific detection kit disclosed by the invention, the recombinant Mycobacterium paratuberculosis membrane protein antigen is adopted as a core detection component, and the antigen has high specificity and can accurately identify paratuberculosis positive serum and effectively distinguish positive and negative samples; meanwhile, prokaryotic expression and purification are carried out on the specific membrane protein of the mycobacterium paratuberculosis for the first time, and a novel sheep paratuberculosis indirect ELISA diagnosis method with high sensitivity and specificity based on the protein as an antigen is established.

The application discloses a kind of neutrophil membrane fusion liposome biomimetic nanomedicine carrier and its preparation method and application, belong to medical field.The carrier includes liposome and the neutrophil membrane fused to liposome;Liposome raw materials include DOPE, DPPC and cholesterol, and mass ratio is 6:3:1 in turn;Liposome and membrane protein mass ratio is 1:1.The application establishes quantitative analysis strategy based on NanoFCM, can accurately evaluate the fusion efficiency and fusion uniformity of NM@lipos at single particle level.Based on DOPE, the hybridization efficiency of NM@lipos (D) reaches 92.0%, which is significantly higher than that of NM@lipos (L) based on lecithin (70.1%).In in vivo experiment, the tumor enrichment capacity of NM@lipos (D) is increased by 5.1 times compared with Lipos (D) in 24 hours, and shows significantly prolonged circulation time.

The invention discloses a breast milk fat globule membrane protein simulation degree evaluation method based on multi-dimensional similarity weighted fusion, and the method comprises the steps: constructing a breast milk MFGM proteomics database, and obtaining the proteomics data of a to-be-evaluated sample; the method comprises the following steps: obtaining a reference matrix through row screening and column screening based on a breast milk MFGM proteomics database, performing logarithmic transformation on the reference matrix, calculating a mean value and a standard deviation of each feature in the reference matrix, and constructing a Z-score matrix and a missing mask matrix corresponding to the reference matrix; calculating abundance distribution similarity and missing mode similarity of the to-be-evaluated sample; setting a shrinkage coefficient based on the actual overlapping feature number, screening a core protein set according to a set threshold value, and comparing to obtain the missing MFGM protein type of the to-be-detected sample; and constructing a Top-K neighbor center, calculating the feature deviation contribution and abundance difference of the to-be-evaluated sample, and outputting key defect proteins and formula optimization suggestions according to preset feature importance indexes. And the similarity simulation accuracy is improved.

The invention relates to the technical field of biological detection, and particularly discloses an ELISA kit for detecting a neutralizing antibody of a severe fever with thrombocytopenia syndrome virus and an application method of the ELISA kit. The ELISA kit comprises an ELISA plate on which SFTSV receptor LRP1 protein is fixed, and an enzyme-labeled SFTSV Gn-8M, wherein the SFTSV receptor LRP1 protein is fixed on the ELISA plate; the SFTSV Gn-8M is an SFTSV membrane protein Gn mutant designed by the invention, and can be specifically combined with an SFTSV receptor LRP1 protein on an elisa plate, and compared with a standard virus strain Gn protein, the self-designed SFTSV Gn-8M has amino acid mutation of eight sites, has stronger combining capacity with a host cell receptor, and can be used for detecting the SFTSV. The kit disclosed by the invention has the characteristics of high safety, high efficiency, high flux, high specificity, high sensitivity, high stability and the like, and is suitable for large-scale rapid screening of the neutralizing antibody of the severe fever with thrombocytopenia syndrome virus.

This invention discloses a biodegradable brush-shaped polymer drug carrier and its applications, belonging to the field of polymer compound technology. The brush-shaped polymer drug carrier is obtained by a click reaction between a polydisulfide backbone and cationic side chains. The polydisulfide backbone in its structure can undergo a special "sulfhydryl exchange" reaction with free thiol groups present on cell membrane proteins, directly carrying the nucleic acid drug into the cell through the cell membrane, thus completing the delivery of the nucleic acid drug. After entering the body, under the action of glutathione (GSH) which is abundant in the tumor cell cytoplasm, the polydisulfide backbone is broken and degraded, releasing the nucleic acid drug, which is suitable for the delivery of nucleic acid drugs.

The invention provides an organoid membrane protein and intracellular protein immunofluorescence in-situ co-staining method, which comprises the following steps of: sealing and fixing organoid glue drops, adding a mixed solution of membrane protein primary antibody and a Dune phosphate buffer solution containing bovine serum albumin for incubation, performing membrane permeation by using a permeation agent, sealing and washing, and drying to obtain the organoid membrane protein and intracellular protein immunofluorescence in-situ co-staining product. Adding a mixed solution of an intracellular protein primary antibody and a Dune phosphate buffer solution containing bovine serum albumin into the cell plate where the transparent organ-like glue drops are located, incubating and washing, then adding a mixed solution of a membrane protein and a fluorescent secondary antibody of the corresponding species of the intracellular protein, incubating and washing in a dark place, and finally obtaining the membrane protein / intracellular protein fluorescent antibody. And finally, adding a mixed solution of DAPI and a Duncheng phosphate buffer solution, and incubating and washing in a dark place again to obtain the membrane protein and intracellular protein immunofluorescence in-situ co-dyed organoid. According to the method, high-quality and high-fidelity membrane protein and intracellular protein in-situ co-dyeing is successfully realized, the integrity of a three-dimensional structure and the high efficiency of an experimental process are taken into consideration, and the method is convenient to operate, high in repeatability and good in universality.

The invention provides a composite material of plant cell membrane vesicles and cerium-based nano-enzyme. The composite material structurally comprises the plant cell membrane vesicles and the cerium-based nano-enzyme attached to the surfaces of the plant cell membrane vesicles, cerium ions of the cerium-based nano-enzyme and carboxyl groups on the surfaces of the plant cell membrane vesicles form coordination bonds; the plant cell membrane vesicles are from cruciferous plants, and carboxyl groups on the surfaces of the plant cell membrane vesicles comprise free carboxyl groups connected with the surfaces of the plant cell membrane vesicles through-NH-CO-PEGn-structures; the mass ratio of the cerium ions to the plant cell membrane protein is (0.1-0.5): 1. The invention also provides a method for preparing the composite material and application of the composite material in sepsis treatment. The composite material can specifically adsorb endotoxin and efficiently degrade the endotoxin, can be used for preventing / rescuing endotoxin-induced cell inflammation, and can also effectively relieve organ failure of sepsis model mice.

The application discloses a Vibrio harveyi oral vaccine and a preparation method and application thereof. The application uses a lactococcus lactis NZ9000 expression system, modifies transformation parameters, effectively expresses Vibrio harveyi OmpU protein, constructs a lactococcus lactis (NZ9000) engineering bacterium expressing Vibrio harveyi outer membrane protein (OmpU), develops an oral vaccine against Vibrio harveyi infection, aims to reduce the infection of economic animals in seawater aquaculture by oral administration, provides a new scheme for dealing with the harm of Vibrio harveyi infection and antibiotic resistance and the like, promotes the breeding of fry and fingerlings, and promotes the development of biological agriculture and related industries. The strategy is expected to overcome the problems of traditional injection vaccines, such as inconvenient operation and great stress, and can provide a new technical scheme for reducing the dependence of the aquaculture industry on antibiotics and promoting the establishment of a green and healthy breeding mode.

The invention relates to the field of biological medicine, in particular to application of disulram in preparation of an orthopoxvirus inhibitor, the disulram is specifically combined with palmitic acid on MPXV gp045 membrane protein to show a remarkable inhibition effect on orthopoxviruses, and when IC50 of the disulram is 825nM, diffusion of the orthopoxviruses can be remarkably inhibited; in HeLa and Huh7.5. 1 cells, when IC50 is 3022nM and 7125nM respectively, formation of EEV can be remarkably inhibited, so that further transmission of orthopoxvirus is prevented, and a more comprehensive intervention means is provided for treatment of orthopoxvirus resistance.

The invention provides an application of a human C1orf186 gene or a human C1orf186 protein in preparation of a targeted therapeutic drug for ovarian cancer, and relates to the technical field of biomedical engineering. The invention relates to an application of a human C1orf186 gene or a human C1orf186 protein in preparation of an ovarian cancer targeted therapy drug. Experiments prove that C1orf186 is an ovarian cancer cell surface specific membrane protein molecule, a C1orf186 positive cell population has tumor stem cell characteristics, and prepared human C1orf186 lentivirus packaging plasmids and other targeted therapeutic drugs have an obvious inhibition effect on the growth of ovarian cancer. Therefore, the invention provides a specific target C1orf186 for molecular therapy of the ovarian cancer, also provides several targeted drug types, and more importantly provides a thought for treating the ovarian cancer by using the anti-C1orf186 targeted drug, thereby laying a foundation for deeply researching the function of the C1orf186. Meanwhile, the invention provides reliable theoretical basis and experimental data for clinical treatment of ovarian cancer, and has important significance and wide prospects.

This invention discloses an antigen and vaccine preparation based on dominant Brucella epitopes, and their application, belonging to the field of recombinant subunit vaccine technology. The antigen is composed of CTL epitopes, HTL epitopes, and B-cell epitopes tandemly, and its amino acid sequence is shown in SEQ ID NO.1. Based on screened dominant CTL epitopes, HTL epitopes, and B-cell epitopes of the Omp25 and Omp31 outer membrane proteins, this invention constructs a novel antigen fusion polypeptide. The vaccine prepared based on this polypeptide effectively activates a significant dual immune response, enhancing cellular immunity while inducing the body to produce high levels of specific antibodies. It also provides good protection against organ damage caused by bacterial infection, offering better immune response and protective efficacy against Brucella, laying the foundation for the development of Brucella recombinant subunit vaccines.

The present application belongs to the field of microbial culture, and particularly relates to a culture medium for reducing expression of surface polysaccharide of Vibrio parahaemolyticus. The formula of the polysaccharide low-expression culture medium is selected from specific proportion of nutritional components and specific conditions for inhibiting polysaccharide expression, so that the expression amount of surface lipopolysaccharide and capsule polysaccharide of Vibrio parahaemolyticus after the culture medium is increased is lower than the expression amount of polysaccharide of Vibrio parahaemolyticus after normal culture, the expression of surface lipopolysaccharide and capsule polysaccharide can be inhibited to a certain extent, the surface of the bacterial body can better expose outer membrane protein, and the immunodetection of Vibrio parahaemolyticus is facilitated. The present application provides a technical basis for developing a complete immunodetection method of Vibrio parahaemolyticus.

A method for predicting vertigo targets using membrane protein-specific weighted interaction enhancement belongs to the interdisciplinary field of bioinformatics and machine learning. This invention uses vertigo membrane protein targets as the core adaptation object, constructing a complete technical chain of "membrane protein-specific multi-dimensional feature input → MRMR feature screening → membrane protein-specific feature correlation weighting – cross-view interaction enhancement fusion → normalization processing → SVM classification prediction." All parameters are fixed and optimized throughout the process, requiring no adjustment based on test data. Through specific embodiment testing and multi-dimensional verification, it is proven that the method's prediction results are realistic, effective, and stable. The prediction accuracy and efficiency are significantly better than existing mainstream methods, and it is currently one of the few dedicated prediction methods specifically designed for vertigo membrane protein targets, filling a gap in existing technology.

The present disclosure provides a polynucleotide comprising an expression cassette of a membrane protein linked to one or more additional expression cassettes for expressing one or more additional genes, the expression cassette of the membrane protein comprising a transmembrane domain and an extracellular domain, the extracellular domain comprising a recognition sequence, and one or more additional expression cassettes for expressing one or more additional genes, the one or more additional expression cassettes being linked to the one or more additional expression cassettes. The recognition sequence can be specifically recognized by the antibody of the recognition sequence. The invention also provides a vector and a cell containing the polynucleotide, and a method for transferring an exogenous gene into a cell and screening the cell by using the polynucleotide or the vector.

This invention discloses an enhanced CAR-T cell (CARTAC) capable of secreting a targeted membrane protein degrader and its applications. While retaining specific killing function, this cell can expand locally in tumors and continuously secrete the bispecific adaptor molecule scTAC. scTAC can recruit E3 ubiquitin ligases, mediate ubiquitination of tumor cell surface membrane proteins (such as PD-L1), and achieve targeted degradation via the lysosomal pathway, effectively reversing the immunosuppressive microenvironment, overcoming antigen heterogeneity, and eliminating antigen-negative tumor cells through the bystander effect. This invention also utilizes the efficient endocytosis properties of EGFR to design scTAC-dual, which can further enhance degradation efficiency. In various lung cancer mouse models, CARTAC-dual exhibited excellent tumor infiltration capacity, low exhaustion levels, and sustained antitumor activity, without systemic toxicity. This invention integrates the targeted killing and protein degradation delivery functions of CAR-T cells, not only enhancing the control effect on solid tumors but also possessing target scalability, making it suitable for the universal upgrading of various CAR-T products.

The invention belongs to the technical field of molecular biology, and discloses a truncated outer membrane protein of klebsiella pneumoniae and application thereof. The invention provides an outer membrane protein Lol B of klebsiella pneumoniae, which can be used for immunizing to induce a protective antibody aiming at various serotypes of klebsiella pneumoniae and killing the klebsiella pneumoniae. Specifically, the outer membrane protein Lol B immune serum can efficiently kill Klebsiella pneumoniae, and when a mouse immunized by the outer membrane protein Lol B immune serum is attacked by K1, K2 and K6 serotype Klebsiella pneumoniae, the mouse can be completely protected to survive, and the trend of weight loss of the mouse is remarkably reduced. Therefore, the outer membrane protein Lol B provided by the invention has a clinical application value for preventing and treating klebsiella pneumoniae infection.

The invention discloses application of rutin hydrate in preventing and treating repeated embryo planting failure, and belongs to the technical field of assisted reproduction. It is found for the first time that CD36 is a key membrane protein for lipid transport and uptake of EECs, rutin hydrate competitively inhibits combination of CD36 and natural ligands of CD36, abnormal lipid excessive uptake is remarkably blocked, lipid accumulation and lipid toxicity damage in cells are effectively relieved, and the effect of inhibiting EECs lipid transport and uptake is achieved. And finally, the endometrial receptivity defect related to RIF is reversed, and the embryo adhesion and implantation capability is remarkably improved. Therefore, rutin hydrate provides a brand new strategy for developing targeted therapy drugs for RIF, especially for lipid metabolism disorder type endometrial receptivity badness, and has remarkable clinical application and transformation prospects.

The invention belongs to the field of biomedical technology and nano material preparation, and discloses a selenium-based targeted protein degradation nano material as well as a preparation method and application thereof. An antibody of a target protein is connected to the surface of nano-selenium through dopamine hydrochloride, and the universal selenium-based targeted protein degradation nano-material is obtained. The preparation method is simple in step and easy to implement, and the development process of the traditional TPD technology is simplified. In addition, the selenium-based targeted protein degradation nano material can also degrade membrane protein and cytoplasm protein at the same time, and the limitation that the membrane protein or cytoplasm protein can only be selectively degraded in the existing TPD technology is overcome, so that the curative effect of immunotherapy is enhanced. In addition, under X rays, the selenium-based targeted protein degradation nano material has a radiation sensitization effect. Therefore, the selenium-based targeted protein degradation nano material can be used for preparing antitumor drugs or used as an X-ray sensitizer.

To provide a high-affinity monoclonal antibody for a His-tag added to the C terminus of membrane protein.SOLUTION: The present invention provides a monoclonal antibody for a histidine tag (His-tag) or an antigen-binding fragment thereof, wherein the monoclonal antibody recognizes, as an epitope, a His-tag added to the C terminus of a membrane protein.SELECTED DRAWING: None

The invention discloses an engineered protein and application thereof in mediating non-ubiquitination degradation, and belongs to the technical field of biological medicine. The structural domains CATCH1 and CATCH2 of the MIDN protein and the region between the structural domains CATCH1 and CATCH2 are modified for the first time, the modification mode comprises the steps that the structural domains CATCH1 and CATCH2 and the region between the structural domains CATCH1 and CATCH2 are replaced with antibodies or polypeptides, then structure or sequence optimization is conducted on the basis, and the obtained MIDN engineered protein not only retains the proteasome binding capacity of MIDN, but also has the advantages of being capable of improving the protein quality and the like. According to the present invention, the MIDN-based target protein degradation system has the MIDN-based target protein degradation system, can expand the target range to the membrane protein or the cytoplasm protein, can improve the degradation efficiency of the MIDN-based target protein degradation system, further has the antibody-mediated target protein specificity so as to achieve the pathological / physiological protein distinguishing effect, and does not have the obvious toxicity; therefore, the engineered protein provided by the invention has a good application prospect.

The invention belongs to the technical field of proteomics detection, and particularly relates to a method for detecting mouse liver neomembrane proteome based on an orthogonal translation system and a mouse strain containing an SORT-KASM module. Comprising the following steps: (S.1) constructing a conditionally expressed SORT-KASM transgenic mouse strain; (S.2) activating the expression of the SORT-KAS M by a tissue specific Cre system; (S.3) giving unnatural amino acid ingestion to the mouse; and (S.4) carrying out biotin labeling coupling on non-natural amino acids in the proteome through an azide-alkyne click reaction. According to the detection method, the space and time high resolution of the liver tissue is achieved, the membrane protein has the high-coverage marking capacity, the low-abundance newborn protein has the high-sensitivity marking capacity, good stability is achieved, and the membrane protein participates in the important physiological processes such as substance transfer, energy metabolism and steady state maintaining; the innovation of the detection method provides a new thought for researching the liver cell membrane proteome.

The invention discloses a cell membrane in-situ drug membrane protein target screening method based on variable configuration DNA, and belongs to the technical field of biological medicine. Two pairs of functionalized nucleic acid structures are constructed, the first pair is S1S2 semi-complementary DNA double strands, the second pair is S3S4 DNA-RNA hybrid double strands, and the S1S2 structure is covalently coupled to a non-natural amino acid site-directed modified membrane protein through a click chemical reaction in a living cell to realize tagging of the membrane protein; when the candidate drug coupled in S3 interacts with the membrane protein, triggering an allosteric response system to release the tagged chain in S1; the released DNA tag is subjected to PCR amplification and sequencing, and accurate identification and analysis of a membrane protein target are realized according to a tag sequence. The invention provides a high-specificity and non-in-vitro drug membrane protein target screening technology. According to the technology, active compound discovery or accurate screening of drug membrane protein targets in a living cell in-situ environment can be realized.